PIK3CA and glioblastoma: Furthermore, we found a significant reduction in NAD+ and glutamate metabolites as well as decreased glucose uptake and lactate secretion under PI3K-mTOR inhibition (NVP-BEZ235 treatment), suggesting decreased glycolytic metabolism in GBM.